Influence of nonspecific brain and plasma binding on CNS exposure: implications for rational drug discovery

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Biopharmaceutics & drug disposition

• Publication date

  2002-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1002/bdd.325PMID 12415573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Property-based design: optimization of drug absorption and pharmacokinetics.

  2001cited by this paper
• Pharmacokinetic and Pharmacodynamic Implications of P‐glycoprotein Modulation

  2001cited by this paper
• Lipophilicity in PK design: methyl, ethyl, futile

  2001cited by this paper
• P-glycoprotein efflux at the blood-brain barrier mediates differences in brain disposition and pharmacodynamics between two structurally related neurokinin-1 receptor antagonists.

  2001cited by this paper
• Development of an In Situ Mouse Brain Perfusion Model and its Application to mdr1a P-Glycoprotein-Deficient Mice

  2000cited by this paper
• Penetration of Amitriptyline, but Not of Fluoxetine, into Brain is Enhanced in Mice with Blood-Brain Barrier Deficiency Due to Mdr1a P-Glycoprotein Gene Disruption

  2000cited by this paper
• Physiologically based pharmacokinetics of digoxin in mdr1a knockout mice.

  1999cited by this paper
• Comparative pharmacokinetics of vinblastine after a 96-hour continuous infusion in wild-type mice and mice lacking mdr1a P-glycoprotein.

  1999cited by this paper
• Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration.

  1999cited by this paper
• In vitro models of the blood-brain barrier.

  1998cited by this paper
• The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors.

  1998cited by this paper
• In Vitro Permeability Across Caco-2 Cells (Colonic) Can Predict In Vivo (Small Intestinal) Absorption in Man—Fact or Myth

  1997cited by this paper
• Distributed model analysis of 3'-azido-3'-deoxythymidine and 2',3'-dideoxyinosine distribution in brain tissue and cerebrospinal fluid.

  1997cited by this paper
• Kinetic evidence for active efflux transport across the blood-brain barrier of quinolone antibiotics.

  1997cited by this paper
• Quantitative brain microdialysis study on the mechanism of quinolones distribution in the central nervous system.

  1997cited by this paper
• Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins.

  1997cited by this paper
• P-glycoprotein in the blood-brain barrier of mice influences the brain penetration and pharmacological activity of many drugs.

  1996cited by this paper
• Computation of brain-blood partitioning of organic solutes via free energy calculations.

  1996cited by this paper
• Brain efflux index as a novel method of analyzing efflux transport at the blood-brain barrier.

  1996cited by this paper
• Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs.

  1994cited by this paper
• Hydrogen bonding. 33. Factors that influence the distribution of solutes between blood and brain.

  1994cited by this paper
• Prediction of drug distribution in distribution dialysis and in vivo from binding to tissues and blood.

  1993cited by this paper
• Tissue Binding versus Plasma Binding of Drugs: General Principles and Pharmacokinetic Consequences

  1991cited by this paper
• Development of a new physicochemical model for brain penetration and its application to the design of centrally acting H2 receptor histamine antagonists.

  1988cited by this paper
• Prediction of drug distribution in vivo on the basis of in vitro binding data.

  1987cited by this paper
• Physiologic pharmacokinetic models and interanimal species scaling.

  1985cited by this paper
• An in situ brain perfusion technique to study cerebrovascular transport in the rat.

  1984cited by this paper
• Comparison between in‐vivo and in‐vitro tissue‐to‐plasma unbound concentration ratios (Kp,f) of quinidine in rats

  1984cited by this paper
• Binding of drugs to tissues.

  1983cited by this paper
• Distributed model for drug delivery to CSF and brain tissue.

  1983cited by this paper
• In vitro andin vivo evaluation of the tissue-to-blood partition coefficient for physiological pharmacokinetic models

  1982cited by this paper
• A method to estimate binding constants at variable protein concentrations

  1979influential reference
• Commentary: a physiological approach to hepatic drug clearance.

  1975cited by this paper
• A physiological approach to hepatic drug clearance

  1975cited by this paper
• FACTORS AFFECTING DRUG METABOLISM

  1971cited by this paper
• Blood Levels of Drug at the Equilibrium State after Multiple Dosing

  1965cited by this paper

• Development and validation of an LC-MS/MS method for simultaneous quantification of p-Chloroamphetamine in plasma and brain: application to pharmacokinetic and brain distribution studies in mice

  2026cites this paper
• Structure-guided optimization of small molecules targeting the yeast casein kinase, Yck2, as a therapeutic strategy to combat Candida albicans

  2025cites this paper
• LC-MS/MS Assay for Quantification of DA-1241, a Novel GPR119 Agonist, in Animal and Human Plasma: Application to Preclinical Pharmacokinetic Studies.

  2025cites this paper
• Applications of contemporary tools to measure plasma protein binding of targeted protein degraders.

  2025cites this paper
• Comparative analysis of the uptake of the H+/OC antiporter substrate oxycodone across and into brain endothelial and parenchymal cells with in vitro–in vivo extrapolation

  2025cites this paper
• Assessing central nervous system drug delivery

  2025cites this paper
• Structure-guided optimization of small molecules targeting Yck2 as a strategy to combat Candida albicans

  2025cites this paper
• Evaluation of various experimental conditions and mechanistic static versus dynamic models to predict time-dependent CYP3A4/5 inhibition potential of drugs.

  2025cites this paper
• Preclinical Systemic Pharmacokinetics, Dose Proportionality, and Central Nervous System Distribution of the ATM Inhibitor WSD0628, a Novel Radiosensitizer for the Treatment of Brain Tumors

  2024cites this paper
• On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

  2024cites this paper
• Determining tissue distribution of the oral antileishmanial agent miltefosine: a physiologically-based pharmacokinetic modeling approach

  2024cites this paper
• Central Nervous System Distributional Kinetics of Selected Histone Deacetylase Inhibitors.

  2024cites this paper
• Formulation-dependent differences in paclitaxel distribution to anatomical sites relevant to chemotherapy-induced peripheral neuropathy

  2024cites this paper
• Regional distribution of unbound eletriptan and sumatriptan in the CNS and PNS in rats: implications for a potential central action

  2024cites this paper
• Application of machine learning to predict unbound drug bioavailability in the brain

  2024cites this paper
• A workflow to practically apply true dose considerations to in vitro testing for Next Generation Risk Assessment.

  2024cites this paper
• Region-independent active CNS net uptake of marketed H+/OC antiporter system substrates

  2024cites this paper
• Brain Targeting Nanomedicines: Pitfalls and Promise

  2024cites this paper
• Improving In Vitro–In Vivo Extrapolation of Clearance Using Rat Liver Microsomes for Highly Plasma Protein-Bound Molecules

  2024cites this paper
• Discovery of 6,7-Dihydropyrazolo[1,5-a]pyrazin-4(5H)-one Derivatives as mGluR2 Negative Allosteric Modulators with In Vivo Activity in a Rodent's Model of Cognition.

  2024cites this paper
• Factors Influencing the Central Nervous System (CNS) Distribution of the Ataxia Telangiectasia Mutated and Rad3-Related Inhibitor Elimusertib (BAY1895344): Implications for the Treatment of CNS Tumors

  2024cites this paper
• Experimental and Computational Methods to Assess Central Nervous System Penetration of Small Molecules

  2024cites this paper
• Analysis of the contributing role of drug transport across biological barriers in the development and treatment of chemotherapy-induced peripheral neuropathy

  2024cites this paper
• Pharmacokinetics of Panobinostat: Interspecies Difference in Metabolic Stability

  2024cites this paper
• Active CNS delivery of oxycodone in healthy and endotoxemic pigs

  2024cites this paper
• Blood–brain barrier transporters: a translational consideration for CNS delivery of neurotherapeutics

  2024cites this paper
• Designing drugs optimized for both blood–brain barrier permeation and intra-cerebral partition

  2023cites this paper
• Pharmacokinetics of Novel Dopamine Transporter Inhibitor CE-123 and Modafinil with a Focus on Central Nervous System Distribution

  2023cites this paper
• On-target, dual aminopeptidase inhibition provides cross-species antimalarial activity

  2023cites this paper
• Developmental changes in the extent of drug binding to rat plasma proteins

  2023cites this paper
• Development and validation of PAMPA-BBB QSAR model to predict brain penetration potential of novel drug candidates

  2023cites this paper
• Development of a Rat Physiologically Based Kinetic Model (PBK) for three Organophosphate Flame Retardants (TDCIPP, TCIPP, TCEP).

  2023cites this paper
• Active Uptake of Oxycodone at Both the Blood-Cerebrospinal Fluid Barrier and The Blood-Brain Barrier without Sex Differences: A Rat Microdialysis Study

  2023cites this paper
• Increased In Vivo Exposure of N-(4-Hydroxyphenyl) Retinamide (4-HPR) to Achieve Plasma Concentrations Effective against Dengue Virus

  2023cites this paper
• Preclinical data do not support the use of amiodarone or dronedarone as antiparasitic drugs for Chagas disease at the approved human dosing regimen

  2023cites this paper
• Central Nervous System Distribution of Panobinostat in Preclinical Models to Guide Dosing for Pediatric Brain Tumors

  2023cites this paper
• Selective and brain-penetrant lanosterol synthase inhibitors target glioma stem-like cells by inducing 24(S),25-epoxycholesterol production.

  2023cites this paper
• FDA approved drugs with antiviral activity against SARS-CoV-2: From structure-based repurposing to host-specific mechanisms

  2023cites this paper
• Recent advances in the in vitro and in vivo methods to assess impact of P‐glycoprotein and breast cancer resistance protein transporters in central nervous system drug disposition

  2023cites this paper
• Using Counter Equilibrium Dialysis (CED) to Increase Confidence in the Measurement of Free Fraction for Challenging Compounds.

  2023cites this paper
• DNDI-6174, a preclinical candidate for visceral leishmaniasis that targets the cytochrome bc1 complex

  2023cites this paper
• Identification of FDA Approved Drugs with Antiviral Activity against SARS-CoV-2: A Tale from structure-based drug repurposing to host-cell mechanistic investigation

  2023cites this paper
• Differential Blood–Brain Barrier Transport and Cell Uptake of Cyclic Peptides In Vivo and In Vitro

  2023cites this paper
• Antiviral effects and tissue exposure of tetrandrine against SARS‐CoV‐2 infection and COVID‐19

  2023cites this paper
• Development and use of a high-throughput screen to identify novel modulators of the corticotropin releasing factor binding protein

  2022cites this paper
• Imaging Leucine-Rich Repeat Kinase 2 In Vivo with 18F-Labeled Positron Emission Tomography Ligand.

  2022cites this paper
• Absorption, distribution, metabolism, and excretion of [14C]Mefuparib (CVL218), a novel PARP1/2 inhibitor, in rats

  2022cites this paper
• L-type Amino Acid Transporter 1 Utilizing Ferulic Acid Derivatives Show Increased Drug Delivery in the Mouse Pancreas Along with Decreased Lipid Peroxidation and Prostaglandin Production

  2022cites this paper
• QSAR model to predict Kp,uu,brain with a small dataset, incorporating predicted values of related parameter

  2022cites this paper
• Consideration of Fractional Distribution Parameter fd in the Chen and Gross Method for Tissue-to-Plasma Partition Coefficients: Comparison of Several Methods

  2022cites this paper
• Murine Central Nervous System and Bone Marrow Distribution of the Aurora A Kinase Inhibitor Alisertib: Pharmacokinetics and Exposure at the Sites of Efficacy and Toxicity

  2022cites this paper
• Inhibition of P2X7 receptors by Lu AF27139 diminishes colonic hypersensitivity and CNS prostanoid levels in a rat model of visceral pain

  2022cites this paper
• New Drug Delivery Systems Developed for Brain Targeting

  2022cites this paper
• To Measure is to Know: A Perspective on the Work of Dr. Margareta Hammarlund-Udenaes

  2022cites this paper
• Role of the Efflux Transporters Abcb1 and Abcg2 in the Brain Distribution of Olaparib in Mice.

  2022cites this paper
• Prediction Models for Brain Distribution of Drugs Based on Biomimetic Chromatographic Data

  2022cites this paper
• Central Nervous System Delivery of the Catalytic Subunit of DNA-Dependent Protein Kinase Inhibitor Peposertib as Radiosensitizer for Brain Metastases

  2022cites this paper
• Pharmacoproteomics of Brain Barrier Transporters and Substrate Design for the Brain Targeted Drug Delivery

  2022cites this paper
• Design and Measurement of Drug Tissue Concentration Asymmetry and Tissue Exposure-Effect (Tissue PK-PD) Evaluation.

  2022cites this paper
• 10-DEBC Hydrochloride as a Promising New Agent against Infection of Mycobacterium abscessus

  2022cites this paper
• In Vitro to In Vivo Extrapolation Linked to Physiologically Based Pharmacokinetic Models for Assessing the Brain Drug Disposition

  2022cites this paper
• Identification of a Cardiac Glycoside Exhibiting Favorable Brain Bioavailability and Potency for Reducing Levels of the Cellular Prion Protein

  2022cites this paper
• Evaluation of the Efficacy of the Hypocretin/orexin Receptor Agonists TAK-925 and ARN-776 in Narcoleptic Orexin/tTA; TetO-DTA Mice

  2022cites this paper
• Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity S

  2022cites this paper
• Understanding the Blood‐Brain Barrier and Beyond: Challenges and Opportunities for Novel CNS Therapeutics

  2022cites this paper
• Unbound Brain-to-Plasma Partition Coefficient, Kp,uu,brain—a Game Changing Parameter for CNS Drug Discovery and Development

  2022cites this paper
• Brain Distribution of Berzosertib: An Ataxia Telangiectasia and Rad3-Related Protein Inhibitor for the Treatment of Glioblastoma

  2021cites this paper
• In Vivo Efficacy of Tesevatinib in EGFR-Amplified Patient-Derived Xenograft Glioblastoma Models May Be Limited by Tissue Binding and Compensatory Signaling

  2021cites this paper
• Development and application of a physiologically based pharmacokinetic model for entrectinib in rats and scale-up to humans: Route-dependent gut wall metabolism.

  2021cites this paper
• Brain-to-Plasma Concentration Ratio and Unbound Partition Coefficient

  2021cites this paper
• Identification of Atovaquone as and Mebendazole as Repurposed Drugs with Antiviral Activity against SARS-CoV-2 (Version 5)

  2021cites this paper
• Factors Influencing Luciferase-Based Bioluminescent Imaging in Preclinical Models of Brain Tumor

  2021cites this paper
• PPARα and PPARγ activation is associated with pleural mesothelioma invasion but therapeutic inhibition is ineffective

  2021cites this paper
• Unbound Brain-to-Plasma Partition Coefficient Determination

  2021cites this paper
• X-ray Structure-Guided Discovery of a Potent, Orally Bioavailable, Dual Human Indoleamine/Tryptophan 2,3-Dioxygenase (hIDO/hTDO) Inhibitor That Shows Activity in a Mouse Model of Parkinson's Disease.

  2021cites this paper
• Discovery of First-in-Class Peptidomimetic Neurolysin Activators Possessing Enhanced Brain Penetration and Stability.

  2021cites this paper
• Systematic evaluation of structure-property relationships and pharmacokinetics in 6-(hetero)aryl-substituted matched pair analogs of amiloride and 5-(N,N-hexamethylene)amiloride.

  2021cites this paper
• Next generation risk assessment (NGRA): Bridging in vitro points-of-departure to human safety assessment using physiologically-based kinetic (PBK) modelling - A case study of doxorubicin with dose metrics considerations.

  2021cites this paper
• Harnessing Preclinical Data as a Predictive Tool for Human Brain Tissue Targeting.

  2021cites this paper
• Preliminary in vitro approach to evaluate the drug-drug interaction potential of EST73502, a dual µ-opioid receptor partial agonist and σ1 receptor antagonist

  2021cites this paper
• Title : Brain distribution of berzosertib : an ATR inhibitor for the treatment of glioblastoma

  2021cites this paper
• Assessment of Metabolic Interaction between Repaglinide and Quercetin via Mixed Inhibition in the Liver: In Vitro and In Vivo

  2021cites this paper
• Antisense Oligonucleotide In Vitro Protein Binding Determination in Plasma, Brain, and Cerebral Spinal Fluid Using Hybridization LC-MS/MS

  2021cites this paper
• Central Nervous System Distribution of an Opioid Agonist Combination with Synergistic Activity

  2021cites this paper
• Brain penetration and efficacy of tepotinib in orthotopic patient-derived xenograft models of MET-driven non-small cell lung cancer brain metastases.

  2021cites this paper
• Enhancing Brain Retention of a KIF11 Inhibitor Significantly Improves its Efficacy in a Mouse Model of Glioblastoma

  2020cites this paper
• Biological barriers, and the influence of protein binding on the passage of drugs across them

  2020cites this paper
• A generic PBTK model implemented in the MCRA platform: Predictive performance and uses in risk assessment of chemicals.

  2020cites this paper
• Strategy for Determining the Free Fraction of Labile Covalent Modulators in Plasma Using Equilibrium Dialysis.

  2020cites this paper
• Targeting of Perforin Inhibitor into the Brain Parenchyma Via a Prodrug Approach Can Decrease Oxidative Stress and Neuroinflammation and Improve Cell Survival

  2020cites this paper
• Herb–Drug Interaction of Red Ginseng Extract and Ginsenoside Rc with Valsartan in Rats

  2020cites this paper
• Brain Distribution of Drugs: Pharmacokinetic Considerations.

  2020cites this paper
• L-Type Amino Acid Transporter 1 Enables the Efficient Brain Delivery of Small-Sized Prodrug across the Blood-Brain Barrier and into Human and Mouse Brain Parenchymal Cells.

  2020cites this paper
• Comparable Intestinal and Hepatic First-Pass Effect of YL-IPA08 on the Bioavailability and Effective Brain Exposure, a Rapid Anti-PTSD and Anti-Depression Compound

  2020cites this paper
• The search for brain-permeant NKCC1 inhibitors for the treatment of seizures: Pharmacokinetic-pharmacodynamic modelling of NKCC1 inhibition by azosemide, torasemide, and bumetanide in mouse brain.

  2020cites this paper
• Special Section on Natural Products: Experimental Approaches to Elucidate Disposition Mechanisms and Predict Pharmacokinetic Drug Interactions Mechanisms of Herb-Drug Interactions Involving Cinnamon and CYP2A6: Focus on Time-Dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde s

  2020cites this paper
• Mechanisms of Herb-Drug Interactions Involving Cinnamon and Cytochrome P450 2A6: Focus on Time-dependent Inhibition by Cinnamaldehyde and 2-Methoxycinnamaldehyde

  2020cites this paper
• Plasma pharmacokinetics and distribution of ruxolitinib into skin following oral and topical administration in minipigs.

  2020cites this paper
• Seeking Nonspecific Binding: Assessing the Reliability of Tissue Dilutions for Calculating Fraction Unbound

  2020cites this paper
• Protein Binding and Stability of Drug Candidates: The Achilles’ Heel in In Vitro Potency Assays

  2020cites this paper